Impact of butylphthalide soft capsules on the related factors and quality of life of Parkinson patients with dementia
10.3760/cma.j.issn.1008-6706.2018.01.018
- VernacularTitle:丁苯酞软胶囊对帕金森痴呆患者痴呆相关因子和生活质量的影响
- Author:
Yi DAI
1
;
Lingyu CAI
;
Xinli ZHENG
;
Juan XU
;
Jianxin WU
;
Yuquan WU
;
An MAO
Author Information
1. 解放军第一一七医院神经内科
- Keywords:
Dementia;
Parkinson disease;
Risk factors;
Quality of life;
Butylphthalide
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(1):68-71
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the impact of butylphthalide soft capsules on the related factors and quality of life of Parkinson patients with dementia.Methods 90 Parkinson patients with dementia were selected,and they were divided into the study group and the control group by the random number table method,45 cases in each group.The control group was treated with donepezil hydrochloride combined with routine nursing method,and the study group was treated with butylphthalide soft capsules based on the treatment of the control group.Before and after treatment,the serum C-reactive protein(CRP),recombinant human Parkinson disease protein 7 (PARK7),neurotrophic factor -3 (NT-3) levels of all patients were detected.And the quality of life of patients at admission and discharge were evaluated by the scale of disease self management efficiency and quality of life scale WHO (WHO QOL-BREF),quality of life of the two groups was compared before and after treatment.The Parkinson's Disease Rating Scale (UPDRS) scores was compared between the two groups before and after treatment.Results Before treatment,the dementia related factors and quality of life score,UPDRS score of the two groups had no statistically significant differences (all P ＞ 0.05).After treatment,the dementia related factors of the two groups were all improved,which of the study group improved significantly [CRP:(3.24 ± 0.78) mg/L vs.(6.02 ± 0.95) mg/L,PARK7:(13.15 ± 1.51) μg/L vs.(24.93 ±2.02)μg/L,NT-3:(34.16 ± 3.47) μg/L vs.(26.23 ± 2.97) μg/L,all P ＜0.05].After treatment,the quality of life(QOL) and UPDRS score of the study group were significantly higher than those of the control group [(80.5 ± 12.5) points vs.(66.0 ± 10.3) points,(33.28 ± 2.18) points vs.(41.26 ± 2.54) points,all P ＜ 0.05].Conclusion Butylphthalide soft capsules can effectively improve the dementia related factor of Parkinson patients with dementia,and enhance the quality of life with good effect.
